Back to Journals » OncoTargets and Therapy » Volume 11

CTLA4 tagging polymorphisms and risk of colorectal cancer: a case–control study involving 2,306 subjects

Authors Zou C, Qiu H, Tang W, Wang Y, Lan B, Chen Y

Received 7 May 2018

Accepted for publication 7 June 2018

Published 7 August 2018 Volume 2018:11 Pages 4609—4619

DOI https://doi.org/10.2147/OTT.S173421

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Sanjeev Srivastava


Chen Zou,1,* Hao Qiu,2,* Weifeng Tang,3 Yafeng Wang,4 Bin Lan,5 Yu Chen6–8

1Department of General Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China; 2Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu Province, China; 3Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China; 4Department of Cardiology, The People’s Hospital of Xishuangbanna Dai Autonomous Prefecture Jinghong, Yunnan Province, China; 5Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China; 6Cancer Bio-immunotherapy Center, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China; 7Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian Province, China; 8Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China

*These authors contributed equally to this work

Background: CTLA4 is a candidate gene which has been implicated in the development of colorectal cancer (CRC).
Patients and Methods: To determine the important role of CTLA-4 polymorphisms on risk of CRC, we genotyped four CTLA-4 tagging polymorphisms and calculated crude/adjusted ORs with their 95% CIs. We recruited 1,003 sporadic CRC cases and 1,303 controls.
Results: The findings suggested that CTLA-4 rs231775 G>A polymorphism increased the risk of CRC (homozygote model: adjusted OR=1.40, 95% CI=1.05–1.87, P=0.022; dominant model: adjusted OR=1.19, 95% CI=1.00–1.41, P=0.047; and recessive model: adjusted OR=1.38, 95% CI=1.05–1.82, P=0.021). In a stratified analysis by site of tumor, this association was also found in colon cancer. We also found that CTLA-4 rs231775 GA/AA genotypes might be associated with an increased risk of CRC in Zhenjiang cohort. In addition, we found the CTLA-4 rs16840252 C>T polymorphism was associated with the risk of colon cancer. Haplotype comparison analysis showed that CTLA-4 Grs3087243Crs16840252Crs733618 Ars231775, Grs3087243Crs16840252Trs733618Ars231775, and other haplotypes increased the risk of CRC (P<0.001, <0.001, and 0.002, respectively).
Conclusion: This study evidences an association of CTLA-4 tagging polymorphisms and haplotypes with CRC risk. Additional well-designed studies with large sample sizes are required to confirm our findings.

Keywords: polymorphism, immune, CTLA-4, tagging, colorectal cancer, susceptibility

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]